BioN­Tech bets on dif­fi­cult STING field via small mol­e­cule pact with a Pol­ish biotech

BioN­Tech is beef­ing up its rel­a­tive­ly thin small mol­e­cule pipeline by adding weight to a clin­i­cal­ly dif­fi­cult cor­ner of on­col­o­gy R&D: STING ag­o­nists. To do so, BioN­Tech is team­ing up with a 15-year-old Pol­ish biotech and dol­ing out €40 mil­lion, about $41.5 mil­lion, to start.

The deal is bro­ken in­to two parts: First, BioN­Tech ob­tains an ex­clu­sive glob­al li­cense to de­vel­op and mar­ket Ryvu Ther­a­peu­tics’ STING ag­o­nist port­fo­lio as small mol­e­cules, whether alone or in com­bi­na­tion with oth­er agents.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN